Logo image
Back
The war against pancreatic cancer in 2020-advances on all fronts
Journal article   Peer reviewed

The war against pancreatic cancer in 2020-advances on all fronts

Tejeshwar Jain and Vikas Dudeja
Nature reviews. Gastroenterology & hepatology, Vol.18(2), pp.99-100
02/01/2021
DOI: 10.1038/s41575-020-00410-4
PMID: 33414515

View Online

Abstract

Key advances An endocrine-exocrine axis involving cholecystokinin secretion by remodelled beta-cells drives obesity-mediated pancreatic ductal adenocarcinoma (PDAC) progression, and this process can be intercepted through weight loss strategies4. Novel avenues for stromal manipulation to improve PDAC therapy were identified in the form of LCCR15+ cancer-associated fibroblasts, which can be used to predict immunotherapy resistance7. Whole-exosome sequencing of primary tumour and matched autopsy samples from patients with recurrent PDAC demonstrated treatment-induced genetic bottlenecks and intermetastatic seeding leading to subclonal heterogeneity in the recurrent tumours, also identifying potentially targetable genetic signatures in recurrent disease9. In 2020, important advances were made across three major frontiers of pancreatic ductal adenocarcinoma (PDAC) research: risk factors, therapeutic resistance and tumour recurrence. Pathophysiology of obesity-mediated PDAC initiation was elucidated, novel stromal mechanisms of therapeutic resistance were unveiled and the genetic evolution of recurrent PDAC under therapeutic pressures was tracked in human samples.
 Gastroenterology & Hepatology Life Sciences & Biomedicine Science & Technology

Details

Metrics

1 Record Views
62 Times Cited - Web of Science
Logo image